President Trump’s and Commerce Secretary Howard Lutnick’s family members are positioned to benefit from efforts to overhaul drug sales

Recent developments suggest that family members of President Trump and Commerce Secretary Howard Lutnick stand to gain from proposed changes in the pharmaceutical industry. This raises concerns about potential conflicts of interest and the integrity of the reform efforts, as it appears that personal connections may influence policy decisions that affect millions of Americans.